Palvella Therapeutics PVLA

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$4.42 (-15.79%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Palvella Therapeutics (PVLA) Business Model and Operations Summary
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. It is developing a broad pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Palvella's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations.

Key Insights

Palvella Therapeutics (PVLA) Core Market Data and Business Metrics
  • Latest Closing Price

    $23.59
  • Market Cap

    $267.18 Million
  • Average Daily Trade Volume

    61,371 Shares
  • Total Outstanding Shares

    11.22 Million Shares
  • CEO

    Mr. Wesley H. Kaupinen
  • Dividend

    No dividend
  • IPO Date

    December 16, 2024
  • SIC Description

    Pharmaceutical Preparations
  • Primary Exchange

    NASDAQ
  • Headquarters

    125 Strafford Ave, Wayne, PA, 19087

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends

Recent Headlines From The Web

Latest news, press releases, and media coverage about PVLA from trusted financial sources